Renaissance Technologies’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Renaissance Technologies’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-104,649	Closed	-$297K	–	4237
2023 Q3	$297K	Sell	104,649 -35,151	-25%	-$96.8K	﹤0.01%	2937
2023 Q2	$363K	Sell	139,800 -36,234	-21%	-$75.9K	﹤0.01%	3041
2023 Q1	$320K	Sell	176,034 -53,159	-23%	-$86.4K	﹤0.01%	3084
2022 Q4	$378K	Sell	229,193 -37,628	-14%	-$60.4K	﹤0.01%	3116
2022 Q3	$512K	Sell	266,821 -80,521	-23%	-$210K	﹤0.01%	2920
2022 Q2	$1.04M	Buy	347,342 +249,542	+255%	+$637K	﹤0.01%	2689
2022 Q1	$369K	Buy	97,800 +71,600	+273%	+$408K	﹤0.01%	3368
2021 Q4	$298K	Buy	+26,200	New	+$399K	﹤0.01%	3346

Other funds holding CYT

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return

Renaissance Technologies's CYT Position: Q4 2023 in Review

Renaissance Technologies sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q4 2023, closing a stake of 104,649 shares — an estimated $297K sold.

Renaissance Technologies first reported a position in CYT in Q4 2021 and held it in 8 quarters. The position peaked at $1.04M in Q2 2022. 38 funds tracked by Wall St. Rank hold CYT as of Q4 2023.

Renaissance Technologies reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Renaissance Technologies sold 104,649 Cyteir Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $297K.
Renaissance Technologies first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Renaissance Technologies's Cyteir Therapeutics, Inc. Common Stock position peaked at $1.04M in Q2 2022.
38 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.